Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships
- PMID: 18450004
- DOI: 10.1007/978-1-60327-118-9_16
Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships
Abstract
Quantitative structure-activity relationship (QSAR) analysis is a cornerstone of modern informatics. Predictive computational models of peptide-major histocompatibility complex (MHC)-binding affinity based on QSAR technology have now become important components of modern computational immunovaccinology. Historically, such approaches have been built around semiqualitative, classification methods, but these are now giving way to quantitative regression methods. We review three methods--a 2D-QSAR additive-partial least squares (PLS) and a 3D-QSAR comparative molecular similarity index analysis (CoMSIA) method--which can identify the sequence dependence of peptide-binding specificity for various class I MHC alleles from the reported binding affinities (IC50) of peptide sets. The third method is an iterative self-consistent (ISC) PLS-based additive method, which is a recently developed extension to the additive method for the affinity prediction of class II peptides. The QSAR methods presented here have established themselves as immunoinformatic techniques complementary to existing methodology, useful in the quantitative prediction of binding affinity: current methods for the in silico identification of T-cell epitopes (which form the basis of many vaccines, diagnostics, and reagents) rely on the accurate computational prediction of peptide-MHC affinity. We have reviewed various human and mouse class I and class II allele models. Studied alleles comprise HLA-A*0101, HLA-A*0201, HLA-A*0202, HLA-A*0203, HLA-A*0206, HLA-A*0301, HLA-A*1101, HLA-A*3101, HLA-A*6801, HLA-A*6802, HLA-B*3501, H2-K(k), H2-K(b), H2-D(b) HLA-DRB1*0101, HLA-DRB1*0401, HLA-DRB1*0701, I-A(b), I-A(d), I-A(k), I-A(S), I-E(d), and I-E(k). In this chapter we show a step-by-step guide into predicting the reliability and the resulting models to represent an advance on existing methods. The peptides used in this study are available from the AntiJen database (http://www.jenner.ac.uk/AntiJen). The PLS method is available commercially in the SYBYL molecular modeling software package. The resulting models, which can be used for accurate T-cell epitope prediction, will be made are freely available online at the URL http://www.jenner.ac.uk/MHCPred.
Similar articles
-
New horizons in mouse immunoinformatics: reliable in silico prediction of mouse class I histocompatibility major complex peptide binding affinity.Org Biomol Chem. 2004 Nov 21;2(22):3274-83. doi: 10.1039/B409656H. Epub 2004 Sep 16. Org Biomol Chem. 2004. PMID: 15534705
-
In silico prediction of peptide binding affinity to class I mouse major histocompatibility complexes: a comparative molecular similarity index analysis (CoMSIA) study.J Chem Inf Model. 2005 Sep-Oct;45(5):1415-23. doi: 10.1021/ci049667l. J Chem Inf Model. 2005. PMID: 16180918
-
Toward prediction of class II mouse major histocompatibility complex peptide binding affinity: in silico bioinformatic evaluation using partial least squares, a robust multivariate statistical technique.J Chem Inf Model. 2006 May-Jun;46(3):1491-502. doi: 10.1021/ci050380d. J Chem Inf Model. 2006. PMID: 16711768
-
Quantitative structure-activity relationships and the prediction of MHC supermotifs.Methods. 2004 Dec;34(4):444-53. doi: 10.1016/j.ymeth.2004.06.007. Methods. 2004. PMID: 15542370 Review.
-
Computational vaccinology: quantitative approaches.Novartis Found Symp. 2003;254:102-20; discussion 120-5, 216-22, 250-2. Novartis Found Symp. 2003. PMID: 14712934 Review.
Cited by
-
Rapid microsphere-assisted peptide screening (MAPS) of promiscuous MHCII-binding peptides in Zika virus envelope protein.AIChE J. 2020 Mar;66(3):e16697. doi: 10.1002/aic.16697. Epub 2019 Jun 11. AIChE J. 2020. PMID: 33343002 Free PMC article.
-
Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).Int J Oncol. 2025 Jun;66(6):43. doi: 10.3892/ijo.2025.5749. Epub 2025 May 9. Int J Oncol. 2025. PMID: 40342048 Free PMC article. Review.
-
Structural basis for the differential classification of HLA-A*6802 and HLA-A*6801 into the A2 and A3 supertypes.Mol Immunol. 2013 Oct;55(3-4):381-92. doi: 10.1016/j.molimm.2013.03.015. Epub 2013 Apr 6. Mol Immunol. 2013. PMID: 23566939 Free PMC article.
-
Predicting HLA class I non-permissive amino acid residues substitutions.PLoS One. 2012;7(8):e41710. doi: 10.1371/journal.pone.0041710. Epub 2012 Aug 8. PLoS One. 2012. PMID: 22905104 Free PMC article.
-
Predicting peptide binding affinities to MHC molecules using a modified semi-empirical scoring function.PLoS One. 2011;6(9):e25055. doi: 10.1371/journal.pone.0025055. Epub 2011 Sep 22. PLoS One. 2011. PMID: 21966412 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials